Repeated low-level red-light (RLRL) therapy has been included in the 2025 Myopia Consensus Statement released by the World Society of Paediatric Ophthalmology and Strabismus (WSPOS).
Australian-based Eyerising International, a leader in RLRL technology, has welcomed the move, stating that it “affirms RLRL as an evidence-based and recognised intervention for slowing myopia progression, underscoring the growing body of clinical evidence supporting RLRL therapy’s efficacy in slowing axial elongation”.
The WSPOS statement notes that numerous studies and meta-analyses consistently show RLRL’s effectiveness, with multiple studies also reporting significant potential for axial shortening, particularly in high myopia.
It also acknowledged RLRL’s strong safety track record, with a systematic review concluding the incidence of side effects from RLRL was the lowest of all myopia control interventions at 0.088 per 100 patient-years.
Eyerising International’s RLRL device, the Eyerising Myopia Management Device, has been at the forefront of this relatively new approach to myopia management.
It is the only patented red-light therapy device for myopia management worldwide, with the largest clinical evidence base of more than 30 peer-reviewed publications and extensive post-market surveillance during the past eight years.
It is also reported to be the only red-light device with international regulatory approval outside of China, now available in more than 40 countries, including Australia.
Clinical studies of its efficacy in non-Chinese populations are now under way in 10 countries, with international results coming in from Australia, Japan and Spain confirming similarly strong treatment effects in non-Chinese populations, Eyerising stated.
“We are grateful for the inclusion of RLRL in the WSPOS Myopia Consensus Statement on effective paediatric myopia control options,” said Mr Jason Sun, managing director of Eyerising International.
“It reflects a growing recognition of RLRL’s therapeutic effect and progress over the past few years. We are proud to be pioneering this therapy with a rigorous commitment to safety, science, and innovation.”
The WSPOS 2025 Myopia Consensus Statement serves as a foundational reference for clinicians, researchers, and public health bodies worldwide.
More reading
Studies show growing momentum for red-light technology
Repeated low-level red-light therapy: a guide for clinicians (CPD)
Eyerising International addresses ‘limitations’ of red light study suggesting reduced cone density
